Bentley Endovascular Group AB has secured investments from Keensight Capital, A.P. Moller Holding, and Bonit Capital to support its expansion into the US market and enhance its product offerings.

Target Information

Bentley Endovascular Group AB, headquartered in Stockholm, Sweden, oversees its principal subsidiary, Bentley InnoMed GmbH, as well as Qmedics AG. Bentley InnoMed GmbH specializes in the development, manufacturing, and marketing of implants and catheters aimed at the endovascular treatment of peripheral vascular and aortic diseases. The company has established itself as a leading manufacturer in its sector, while Qmedics AG focuses on producing dilatation balloons, serving as a vital supplier for Bentley InnoMed GmbH. Over the past five years, Bentley InnoMed GmbH has experienced an impressive sales growth of over 20% annually, coupled with strong profitability.

Globally recognized for its high-quality medical devices and exceptional customer service, Bentley Endovascular Group is at the forefront of product innovation. Their advanced medical devices significantly contribute to improving patient care and effectively treating vascular diseases. The Group is committed to offering a comprehensive range of trusted products and superb services for treating aortic and peripheral vascular conditions. Bentley’s strategy is centered on fostering healthy and profitable growth, including exploring substantial opportunities in the US market and potential complementary acquisitions while optimizing their existing marketing and sales network.

Industry Overview

The endovascular medical device industry has been experiencing a strong surge in demand, especially with the growing prevalence of vascular diseases due to an aging population. In Sweden, the healthcare sector is robust, supported by signifi